You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
A - Regimen Name


Disease Site
Gynecologic - Ovary


Regimen Category
Evidence-Informed :

Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR).  Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

Rationale and Uses

For the treatment of advanced or recurrent epithelial ovarian, fallopian tube and primary peritoneal cancers

B - Drug Regimen

75 mg /m² IV Day 1
AUC 4 to 6 IV Day 1

Adjust Carboplatin dose to AUC target (using Calvert formula) as outlined in the "Other Notes" section.

back to top
C - Cycle Frequency


For a usual total of 6 cycles unless disease progression or unacceptable toxicity occurs

D - Premedication and Supportive Measures

Antiemetic Regimen:

Moderate + NK1 antagonist (Carboplatin AUC ≥ 5)
Moderate (Carboplatin AUC < 5)

Other Supportive Care:

Also refer to CCO Antiemetic Recommendations.

Dexamethasone 8 mg bid po for 3 days starting 1 day prior to docetaxel (prevent anaphylaxis / fluid retention.)

E - Dose Modifications

Doses should be modified according to the protocol by which the patient is being treated. The following recommendations have been adapted from clinical trials or product monographs and could be considered.


Dosage with toxicity

Toxicity Type / Counts x 109/L
Toxicity Type / Counts x 109/L
(% previous dose)
Febrile Neutropenia
Grade 4 ANC ≥ 7 days
↓ 1 AUC
Grade 3 rash
Grade 3 Neurotoxicity
↓ by 1 AUC at restart
Restart at 75%. Discontinue if recurs 
Any occurrence of cystoid macular edema     No change Hold and investigate; refer patient promptly to an ophthalmic examination. Discontinue if confirmed.
Other Grade 3 major organ /  non-hematologic
↓ 1 AUC
Grade 4 major organ / non-hematologic
1Prior to retreatment, toxicity should have recovered to ≤ grade 2, ANC to ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L

Hepatic Impairment

AST and/or ALT
Alk Phosp
(% previous dose)
Dose of Carboplatin
> 1.5 X ULN
> 2.5 x ULN
Do not treat
No dose adjustment required
> 3.5 x ULN
> 6 x ULN
Do not treat. Discontinue if treatment already started.

Renal Impairment

  • As creatinine clearance changes, adjust dosage of carboplatin using the Calvert Formula. (See Section: Other Notes)
  • Modification for docetaxel not required.

Dosage in the Elderly

  • No adjustment required , but caution should be exercised in elderly patients with poor performance status who are receiving docetaxel.
  • Caution should be exercised and dose reduction considered as elderly patients may have more severe myelosuppression and neuropathy with carboplatin.

F - Adverse Effects

Refer to DOCEtaxel, CARBOplatin drug monograph(s) for additional details of adverse effects

Very common (50%)

Common (25-49%)

Less common (10-24%)

Uncommon (< 10%),

but may be severe or life-threatening

  • Alopecia
  • Fatigue
  • Myelosuppression +/- infection, bleeding (may be severe)
  • Nausea, vomiting
  • Neuropathy (may be severe)
  • Rash (may be severe)
  • Fluid retention
  • Mucositis
  • Diarrhea
  • Abnormal electrolytes
  • Increased LFTs (may be severe)
  • Nail disorder
  • Nephrotoxicity (may be severe)
  • Hypersensitivity (may be severe)
  • Musculoskeletal pain
  • Ototoxicity
  • Arrhythmia
  • Cardiotoxicity
  • Arterial thromboembolism
  • Venous thromboembolism
  • Cytoid macular edema
  • GI obstruction, perforation
  • DIC
  • Hemolytic uremic syndrome
  • Pneumonitis
  • Seizure
G - Interactions

Refer to DOCEtaxel, CARBOplatin drug monograph(s) for additional details

  • Caution and monitor with nephrotoxic and ototoxic drugs (i.e. aminoglycosides)
  • Caution and monitor INR for patients receiving warfarin
  • Caution and monitor phenytoin levels for patients receiving phenytoin
  • Docetaxel is a substrate of CYP3A4 and PgP. Caution and monitor with inducers and inhibitors of these isoenzymes.
  • Consider docetaxel dose reduction when given with strong CYP3A4 inhibitors
  • Avoid combining docetaxel with dronedarone (severe toxicity reported)
H - Drug Administration and Special Precautions

Refer to DOCEtaxel, CARBOplatin drug monograph(s) for additional details



  • Mix in 100mL to 250mL bag (5% Dextrose or Normal Saline); infuse IV over 15 to 60 minutes.
  • Incompatible with sets, needles or syringes containing aluminum – leads to precipitation and loss of potency.
  • Protect from light.


  • Refer to the respective product monographs for preparation instructions.
  • Mix in 250mL D5W or NS to a maximum concentration of 0.3-0.74 mg/mL. For doses over 185 mg, use a larger volume of the infusion vehicle so the maximum concentration is not exceeded.
  • Infuse through main IV line over 1 hour. 
  • To minimize exposure to DEHP leaching from PVC infusion equipment, use non-PVC (polyolefin, polypropylene) bags and administer through polyethylene-lined infusion sets.
  • To minimize hypersensitivity reactions, docetaxel infusion should be started at a slow rate, then increased incrementally to planned rate.
  • Monitor patient for signs of alcohol intoxication (due to alcohol content in formulation) during and after the infusion.


  • Patients who have a severe hypersensitivity to these drugs or other platinum containing compounds/other drugs formulated with polysorbate 80.
  • Patients with neutrophil counts of <1.5 x 109/L
  • Patients with severe hepatic or renal impairment, severe myelosuppression or bleeding tumours


  • Avoid concomitant use of docetaxel and drugs that inhibit CYP3A4 (See Interactions section).
  • Caution with carboplatin and patients with abnormal renal function or who are receiving concomitant nephrotoxic drugs
  • Use docetaxel with caution in patients with preexisting effusions or ascites.
  • Docetaxel contains ethanol (± 1g/m2; refer to respective product monographs) and may cause drowsiness. Patients should be cautioned regarding driving and the use of machinery immediately after receiving the infusion. Ethanol may be harmful to patients at risk of adverse effects such as those with alcoholism, liver disease, epilepsy and children. Cases of alcohol intoxication have been reported.
  • Carboplatin and docetaxel are not recommended for use in pregnancy (contraindicated with docetaxel). Adequate contraception should be used by both sexes during treatment, and for at least 6 months after the last dose. Breastfeeding is contraindicated with docetaxel and not recommended with carboplatin.
I - Recommended Clinical Monitoring

Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.

Recommended Clinical Monitoring

  • CBC and electrolytes (including magnesium); Baseline and before each treatment
  • Renal and liver function tests; Baseline and before each treatment
  • Clinical toxicity assessment (including infection, bleeding, neurologic, ototoxiciy, musculoskeletal pain, hypersensitivity, lethargy, GI, fluid retention, cutaneous effects, ophthalmic, cardiac, respiratory, thromboembolism); at each visit
  • Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version

Suggested Clinical Monitoring

  • INR in patients receiving warfarin; baseline and regular

back to top
J - Administrative Information

Approximate Patient Visit
2 to 3 hours
Pharmacy Workload (average time per visit)
35.656 minutes
Nursing Workload (average time per visit)
59.167 minutes
K - References

Carboplatin and docetaxel drug monographs, Cancer Care Ontario.

Markman M, Kennedy A, Webster K, et al.  Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001;19:1901-5.

Vorobiof DA, Rapoport BL, Chasen MR, et al.  Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy.  J Gynecol Cancer 2003;13:287-91.

Wang Y, Herrstedt J, Havsteen H, et al.   A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.  BMC Cancer 2014;14:937.

PEBC Advice Documents or Guidelines

June 2019 Updated emetic risk category

back to top
L - Other Notes

Calvert Formula

DOSE (mg) = target AUC X (GFR + 25)

  • AUC = product of serum concentration (mg/mL) and time (min)
  • GFR (glomerular filtration rate) expressed as measured Creatinine Clearance or estimated from Serum Creatinine (by Cockcroft and Gault method or Jelliffe method)

(Calvert AH, Newell DR, Gumbrell LA, et al, Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol, 1989; 7: 1748-1756)

M - Disclaimer

Regimen Abstracts
A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.
Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph.  Full regimen monographs will be published for each ST-QBP regimen as they are developed.
Regimen Monographs
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.